The Claim
Supplementation with 45 μg of menaquinone-7 for 8 weeks has no effect on bone turnover markers (bone alkaline phosphatase or NTX) or coagulation parameters (thrombin peak height or endogenous thrombin potential) in healthy prepubertal children.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Giving 45 micrograms of menaquinone-7 daily for 8 weeks does not change levels of bone turnover markers or blood clotting parameters in healthy children who have not yet reached puberty.
See the scientific wording
Supplementation with 45 μg of menaquinone-7 for 8 weeks does not alter bone turnover markers (bone alkaline phosphatase or NTX) or coagulation parameters (thrombin peak height or endogenous thrombin potential) in healthy prepubertal children, indicating no detectable effect on bone remodeling or hemostasis.
A daily vitamin K2 supplement gets absorbed into the blood and helps change a bone protein so it can bind to minerals in bone, but this change does not speed up or slow down bone building or breakdown, and it does not affect how blood clots.
What the research says
1 studyKids who took a daily vitamin K2 pill for two months didn't show any change in how fast their bones grew or how their blood clotted — even though their bodies used the vitamin better. So the pill didn't hurt or help those processes.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.